PUBLIC AGENDA

2:00 pm  Welcome and Introductions
Karen Johnson, MS, Neurology Project Senior Director
Suzanne Theberge, MPH, Neurology Project Manager

2:15 pm  Measure Discussion
- 1952: Time to Intravenous Thrombolytic Therapy (American Heart Association)
- 0437: STK 04: Thrombolytic Therapy (The Joint Commission)
- 0242: Tissue Plasminogen Activator (t-PA) Considered (AMA-PCPI)
- 2022: Tissue Plasminogen Activator (t-PA) Initiated (AMA-PCPI)
- 0438: STK 05: Antithrombotic Therapy By End of Hospital Day Two (The Joint Commission)
- 0435: STK 02: Discharged on Antithrombotic Therapy (The Joint Commission)
- 0325: Discharged on Antithrombotic Therapy (AMA-PCPI)
- 0439: STK-06: Discharged on Statin Medication (The Joint Commission)

3:50 pm  Public & Member Comment

3:55 pm  Next Steps
Ms. Theberge

4:00 pm  Adjourn